GpTx‐1 and [Ala5,Phe6,Leu26,Arg28]GpTx‐1, two peptideNaV1.7 inhibitors: analgesic and tolerance properties at the spinal level
British Journal of Pharmacology2018Vol. 175(20), pp. 3911–3927
Citations Over TimeTop 15% of 2018 papers
Chao Chen, Biao Xu, Xuerui Shi, Mengna Zhang, Qinqin Zhang, Ting Zhang, Weidong Zhao, Run Zhang, Zilong Wang, Ning Li, Quan Fang
Abstract
Our data indicate that the NaV 1.7 peptide inhibitors GpTx-1 and GpTx-1-71 produce powerful, nontolerance-forming analgesia in preclinical pain models, which might be dependent on the endogenous opioid system. In addition, at the spinal level, the limited side effects imply that these NaV 1.7 peptide inhibitors could be potentially developed as GpTx-1-based drugs for pain relief.
Related Papers
- → Neuropathic pain in patients with sickle cell disease(2013)112 cited
- → Establishment of a Potency Test by ELISA for a Rabies Vaccine for Animal Use in Japan(2003)15 cited
- → The Experimental Study on the continuous Anti-bacterial Potency of Coptidis rhizoma extract on Cultivation of Staphylococcus species(S. aureus, S. epidermidis)(2007)1 cited
- → Potency analysis of cellular therapies: the role of molecular assays(2021)
- → (1983)